Lung delivery of salbutamol by dry powder inhaler (Turbuhaler) and small volume antistatic metal spacer (Airomir CFC-free MDI plus NebuChamber)
Authors:
- Dj ClarkDCDj Clark
- 1 August 1997
- journal article
- clinical trial
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 10 (8) , 1820-1823
Abstract
As a worldwide ban on the use of chlorofluorocarbons (CFCs) in inhaler devices approaches, considerable attention has been focused on the production of CFC-free delivery devices. The aim of our study was to compare the delivery of salbutamol by dry powder inhaler (DPI), Turbuhaler and a CFC-free metered-dose inhaler (MDI), Airomir, used with a novel small volume metal spacer (NebuChamber). Ten healthy volunteers, mean (SEM) age 21 (0.7) yrs were studied in a randomized, single (investigator)-blind cross-over design. Single doses of 1,200 microg salbutamol, from Turbuhaler DPI and Airomir CFC-free MDI via a NebuChamber, were given as 12 sequential 100 microg inhalations over 6 min. The lung delivery of salbutamol was assessed by measuring the plasma salbutamol profile over the first 20 min after inhalation. Plasma salbutamol concentration was expressed as maximal (Cmax) and average (Cav) value. Significant differences (p<0.001) were found between the NebuChamber (N) and the Turbuhaler (T) for salbutamol Cmax and Cav. This amounted to a 1.89 fold difference (95% CI 1.56-2.22) between these devices for Cmax, and a 1.78 fold difference (95% CI 1.42-2.15) for Cav. We have demonstrated that, in vivo, salbutamol from a chlorofluorocarbon-free metered-dose inhaler given via a small volume metal spacer (NebuChamber) produces significantly greater delivery than from an efficient dry powder inhaler (Turbuhaler).Keywords
This publication has 12 references indexed in Scilit:
- Effect of multiple actuations, delayed inhalation and antistatic treatment on the lung bioavailability of salbutamol via a spacer device.Thorax, 1996
- Effect of electrostatic charge, flow, delay and multiple actuations on the in vitro delivery of salbutamol from different small volume spacers for infants.Thorax, 1996
- Lung bioavailability of generic and innovator salbutamol MDIs.Thorax, 1996
- Lung bioavailability of generic and innovator salbutamol metered dose inhalers.Thorax, 1996
- Aerosol Particle Generation from Dry Powder Inhalers: Can They Equal Pressurized Metered Dose Inhalers?Journal of Aerosol Medicine, 1995
- A non-electrostatic spacer for aerosol delivery.Archives of Disease in Childhood, 1995
- Metered-dose inhalers and CFCs: what respiratory physicians need to knowRespiratory Medicine, 1994
- Nebuliser performance, pharmacokinetics, airways and systemic effects of salbutamol given via a novel nebuliser delivery system ("Ventstream").Thorax, 1994
- Comparison of the extrapulmonary β2‐adrenoceptor responses and pharmacokinetics of salbutamol given by standard metered dose‐inhaler and modified actuator deviceBritish Journal of Clinical Pharmacology, 1993
- Beta-adrenoceptor responses to inhaled salbutamol in normal subjectsEuropean Journal of Clinical Pharmacology, 1989